Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Ryan R. Willard"'
Autor:
Marcia Dougan Moore, Yimin Qian, Sheryl M. Gough, Ian Taylor, Mark Bookbinder, John J. Flanagan, Lawrence Snyder, Craig M. Crews, John Bradley, Emma Rousseau, Andrew P. Crew, Ryan R. Willard, Ron Peck, Julian T. Chandler, Gregory Cadelina, Jennifer Pizzano, John Houston, Monica Andreoli
Publikováno v:
Cancer Research. 81:44-44
ARV-471, an estrogen receptor (ER) alpha PROTAC® protein degrader, is a hetero-bifunctional molecule that facilitates the interactions between estrogen receptor alpha and an intracellular E3 ligase complex, leading to the ubiquitylation and subseque
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab165228b8186f02068090ebd0aab12f
https://doi.org/10.1158/1538-7445.am2021-44
https://doi.org/10.1158/1538-7445.am2021-44
Autor:
Andrew P. Crew, Ron Peck, Xin Chen, Deborah A. Gordon, Hanqing Dong, Jennifer Pizzano, John Houston, Jennifer Macaluso, Taavi K. Neklesa, Craig M. Crews, Nicholas Vitale, Ian Taylor, Caterina Ferraro, Lawrence Snyder, Jing Wang, Ryan R. Willard, Marcia Dougan Moore
Publikováno v:
Cancer Research. 81:43-43
Prostate cancer is the second leading cause of cancer death in men in the United States. The androgen receptor (AR) plays critical roles in both early disease and advanced prostate cancer. Current therapeutic approaches targeting the androgen/AR axis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::816bc8632c397c4f312fbaf039fe9f63
https://doi.org/10.1158/1538-7445.am2021-43
https://doi.org/10.1158/1538-7445.am2021-43
Autor:
Andrew P. Crew, Taavi K. Neklesa, Donald P. McDonnell, Craig M. Crews, Shanique B. Alabi, Jemilat Salami, Hanqing Dong, Meizhong Jin, Nick J. Vitale, Jing Wang, Ryan R. Willard
Publikováno v:
Communications Biology, Vol 1, Iss 1, Pp 1-9 (2018)
The androgen receptor is a major driver of prostate cancer and inhibition of its transcriptional activity using competitive antagonists, such as enzalutamide remains a frontline therapy for prostate cancer management. However, the majority of patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51046816fbe40eda42878432d778b9de
https://pubmed.ncbi.nlm.nih.gov/30271980
https://pubmed.ncbi.nlm.nih.gov/30271980
Autor:
Natasha Routly, Giovanna Bergamini, Jeffrey L. Gustafson, Ko Eunhwa, Kristoffer Famm, Paola Grandi, John J. Flanagan, Daniel P. Bondeson, Maria Faelth-Savitski, Afjal Hussain Miah, Nico Zinn, Deborah A. Gordon, Craig M. Crews, Laurens Kruidenier, Paul S. Carter, Ian Edward David Smith, Marcus Bantscheff, Alina Mares, Dennis L. Buckley, John D. Harling, Linda N. Casillas, Sebastien Andre Campos, Ryan R. Willard, Bartholomew J. Votta, Willem den Besten, Satoko Shimamura, Carly S. Cox, Ian Churcher, Katie E Mulholland
Publikováno v:
Nature Chemical Biology. 11:611-617
The current predominant therapeutic paradigm is based on maximizing drug-receptor occupancy to achieve clinical benefit. This strategy, however, generally requires excessive drug concentrations to ensure sufficient occupancy, often leading to adverse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91cded625a4a254a72d85709b447840b
https://doi.org/10.1038/nchembio.1858
https://doi.org/10.1038/nchembio.1858
Autor:
Caterina Ferraro, Jing Wang, Ryan R. Willard, Taavi K. Neklesa, Jennifer Pizzano, John Houston, Ian Taylor, Gan Wang, Nicholas Vitale, Andrew P. Crew, Deborah A. Gordon, Hanqing Dong, Mark Bookbinder, Jennifer Macaluso, Craig M. Crews, Lawrence Snyder
Publikováno v:
Journal of Clinical Oncology. 37:259-259
259 Background: The Androgen Receptor (AR) remains the principal driver of castration-resistant prostate cancer during the transition from a localized to metastatic disease. Most patients initially respond to inhibitors of the AR pathway, but the res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56d2b6c51ddc527683400691399255ce
https://doi.org/10.1200/jco.2019.37.7_suppl.259
https://doi.org/10.1200/jco.2019.37.7_suppl.259
Autor:
John J. Flanagan, Craig M. Crews, John Bradley, Yimin Qian, M Andreoli, Ian Taylor, Jennifer Pizzano, John Houston, AP Crew, Emma Rousseau, Gregory Cadelina, Mark Bookbinder, Ryan R. Willard, Sheryl M. Gough
Publikováno v:
Cancer Research. 79:P5-04
ARV-471, an estrogen receptor (ER) alpha PROTAC, is a hetero-bifunctional molecule that facilitates the interactions between estrogen receptor alpha and an intracellular E3 ligase complex, leading to the ubiquitylation and subsequent degradation of e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65e55cbaa319d75f65dd30cd396576c9
https://doi.org/10.1158/1538-7445.sabcs18-p5-04-18
https://doi.org/10.1158/1538-7445.sabcs18-p5-04-18
Autor:
Jennifer Pizzano, John Houston, Gan Wang, Craig M. Crews, Taavi K. Neklesa, Hanqing Dong, Mark Bookbinder, Kanak Raina, Lawrence Snyder, Zheng Liu, Andrew P. Crew, Ian Taylor, Deborah M. Gordon, Nicholas Vitale, Jing Wang, Jennifer Macaluso, Ryan R. Willard, Caterina Ferraro
Publikováno v:
Cancer Research. 78:5236-5236
The Androgen Receptor (AR) remains the principal driver of castration-resistant prostate cancer during the transition from a localized to metastatic disease. Most patients initially respond to inhibitors of the AR pathway, but the response is often s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e493817f0bd7cf8cba27820a3083221
https://doi.org/10.1158/1538-7445.am2018-5236
https://doi.org/10.1158/1538-7445.am2018-5236
Autor:
Taavi Neklesa, Lawrence B Snyder, Ryan R Willard, Nicholas Vitale, Kanak Raina, Jennifer Pizzano, Deborah A Gordon, Mark Bookbinder, Jennifer Macaluso, Hanqing Dong, Zheng Liu, Caterina Ferraro, Gan Wang, Jing Wang, Craig M Crews, John Houston, Andrew P Crew, Ian Taylor
Publikováno v:
Journal of Clinical Oncology. 36:381-381
381 Background: The Androgen Receptor (AR) remains the principal driver of castration-resistant prostate cancer during the transition from a localized to metastatic disease. Most patients initially respond to inhibitors of the AR pathway, but the res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f4b32ae9ddf689abe5dd5126d9ff9c1
https://doi.org/10.1200/jco.2018.36.6_suppl.381
https://doi.org/10.1200/jco.2018.36.6_suppl.381
Publikováno v:
The International Journal of Artificial Organs. 33:348-361
Two cell lines, PICM-19H and PICM-19B, were derived from the bipotent PICM-19 pig liver stem cell line and assessed for their potential application in artificial liver devices (ALD). The study included assessments of growth rate and cell density in c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8782275c4babf2296aa36ed42546680a
https://doi.org/10.1177/039139881003300603
https://doi.org/10.1177/039139881003300603
Publikováno v:
In Vitro Cellular & Developmental Biology - Animal. 46:11-19
Liver in vitro models are needed to replace animal models for rapid assessment of drug biotransformation and toxicity. The PICM-19 pig liver stem cell line may fulfill this need since these cells have activities associated with xenobiotic phase I and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9818b3794fc7c2e74d2e4c0b1be9f1d9
https://doi.org/10.1007/s11626-009-9244-z
https://doi.org/10.1007/s11626-009-9244-z